105
Participants
Start Date
February 29, 2016
Primary Completion Date
March 31, 2024
Study Completion Date
March 31, 2024
Digoxin (monotherapy)
Oral or IV loading dose: 0.5 mg q 12 h (total 4 doses over 48 hours) followed by Oral maintenance dose: 0.25 mg-1mg/day
Sotalol (monotherapy)
Oral dose: 80 mg TID or 120 mg BID (240 mg/day)
Flecainide (monotherapy)
Oral dose: 100 mg TID (300 mg/day)
Digoxin (dual therapy)
Oral or IV loading dose: 0.5 mg q 8 h (total 4 doses over 32 hours) followed by oral maintenance dose: 0.25 mg-1mg/day
Sotalol (dual therapy)
Oral dose: 160 mg BID (320 mg/day)
Flecainide (dual therapy)
Oral dose:100 mg TID (300 mg/day)
Morgan Stanley Children's Hospital of New York-Presbyterian, New York
Children's National Health System, Washington D.C.
West Virginia University Research Corporation, Morgantown
Vanderbilt University Medical Center, Nashville
Cincinnati Children's Hospital Medical Center, Cincinnati
Children's Hospital of Wisconsin, Milwaukee
Baylor College of Medicine, Houston
Pediatrix Medical Services, Inc,, Austin
Children's Hospital of Colorado, Aurora
University of Utah, Salt Lake City
UCSF Benioff Children's Hospital, San Francisco
Cohen Children's Medical Center, New York
The Royal Women's Hospital, Melbourne
University of Alberta/WCCHN, Edmonton
Mount Sinai Hospital, Toronto
The Hospital for Sick Children, Toronto
CHU Sainte-Justine Hospital, Montreal
UKB Universitätsklinikum BONN, Bonn
Academic Medical Center - AMC, Amsterdam
Leiden University Medical Center - LUMC, Leiden
St George's University Hospital Foundation Trust, London
British Columbia Children's Hospital, Vancouver
Canadian Institutes of Health Research (CIHR)
OTHER_GOV
Edgar Jaeggi
OTHER